CD8A and neoplasm: To build TRTpred, we took advantage of 235 CD8+ clonotypes, annotated as tumor-reactive (n = 112) or non-tumor-reactive (n = 123), curated from ten patients with metastatic melanoma3,19 (Fig. 1b, Extended Data Fig. 1a and Supplementary Table 1).